BOTHELL, Wash and VANCOUVER, British Columbia, Nov. 28, 2017 — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced an agreement with Auckland UniServices Limited, as the commercial arm of the University of Auckland, to provide cytisine for use in…
/Read More
BOTHELL, Wash and VANCOUVER, British Columbia, NOV. 14, 2017 — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced results of a clinical study evaluating the effect of food on the bioavailability of 3mg cytisine. The study evaluated the bioavailability…
/Read More
BOTHELL, Wash and VANCOUVER, British Columbia, November 8, 2017 — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced that Rick Stewart, Chairman and Chief Executive Officer, will present at the 29th Annual Piper Jaffray Healthcare Conference being held on…
/Read More
BOTHELL, Wash and VANCOUVER, British Columbia, November 6, 2017 – Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced that the November 2nd presentation given by Rick Stewart, Chairman and Chief Executive Officer, is now available for on-demand viewing at…
/Read More
Company invites individual and institutional investors and advisors to attend virtualinvestorconferences.com BOTHELL, Wash and VANCOUVER, British Columbia, Oct. 30, 2017 – Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced that Rick Stewart, Chairman and Chief Executive Officer, will be…
/Read More